Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

CASI Pharma Raises $48.5 Million to Acquire New Drugs

publication date: Sep 17, 2018

CASI Pharma, a US-China company, announced a $48.5 private placement that will be used to in-license additional drugs and obtain approvals of its current portfolio of drug candidates. In early 2018, CASI acquired global rights to a portfolio of 29 generic drugs from Sandoz with abbreviated ANDAs submitted in the US. CASI said it would choose some of the generics for China development. The company also has three drugs in-licensed from Spectrum that are currently in China trials. CASI is headquartered in Maryland with R&D operations in Beijing. More details....

Stock Symbol: (NSDQ: CASI)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

ChinaBio® Events


China Showcase 2020

San Francisco, USA

January 12, 2020

ChinaBio Partnering Forum 2020

Suzhou, China

May 6-7, 2020